Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Cells
Maria Grazia FerraroCarlo Irace

Abstract

In this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and resistance. This strategy could allow for new options for breast cancer (BC) interventions, including the triple-negative subtype (TNBC) with poor therapeutic alternatives. BC is currently the second most widespread cancer and the primary cause of cancer death in women. Hence, the availability of novel chemotherapeutic weapons is a basic requirement to fight BC subtypes. Anticancer drugs based on ruthenium are among the most explored and advanced next-generation metallotherapeutics, with NAMI-A and KP1019 as two iconic ruthenium complexes having undergone clinical trials. In addition, many nanomaterial Ru complexes have been recently conceived and developed into anticancer drugs demonstrating attractive properties. In this field, we focused on the evaluation of a Ru(III) complex-named AziRu-incorporated into a suite of both zwitterionic and cationic nucleolipid nanosystems, which proved to be very effective for the in vivo targeting o...Continue Reading

References

Jul 1, 1992·Clinical & Experimental Metastasis·G SavaE Alessio
Nov 1, 1989·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S PacorG Mestroni
Jan 1, 1980·Journal of Inorganic Biochemistry·M J ClarkeA D Kelman
Jun 17, 1998·Clinical & Experimental Metastasis·G SavaG Mestroni
Jan 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G SavaG Mestroni
Nov 14, 2002·International Journal of Pharmaceutics·Marjan BoumaJos H Beijnen
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeany M Rademaker-LakhaiJan H M Schellens
Dec 8, 2004·Current Topics in Medicinal Chemistry·Enzo AlessioGianni Sava
Jul 25, 2006·Nature Reviews. Cancer·Andrew I Minchinton, Ian F Tannock
Apr 11, 2007·Journal of Medicinal Chemistry·Carsten A VockPaul J Dyson
Mar 5, 2009·Chemical Communications : Chem Comm·Mauro VaccaroLuigi Paduano
Dec 19, 2009·Current Opinion in Chemical Biology·Chi-Ming Che, Fung-Ming Siu
Mar 12, 2010·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Petra HeffeterGunda Koellensperger
Feb 1, 2011·Clinical Obstetrics and Gynecology·Sonali Pandya, Richard G Moore
Jun 2, 2011·Dalton Transactions : an International Journal of Inorganic Chemistry·Alberta Bergamo, Gianni Sava
Sep 3, 2011·Breast Cancer Research : BCR·Deborah L Holliday, Valerie Speirs
Sep 8, 2011·Molecular BioSystems·Luca SimeoneLuigi Paduano
Jan 18, 2012·Chemotherapy·Ali I Shamseddine, Fadi S Farhat
Feb 24, 2012·Biomaterials·Gaetano MangiapiaLuigi Paduano
May 16, 2012·Cancer Discovery·Levi A Garraway, Pasi A Jänne
Oct 19, 2012·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Orsolya DömötörEva A Enyedy
Feb 16, 2013·Current Medicinal Chemistry·Zhuo ChenXuhong Qian
Oct 15, 2013·Dalton Transactions : an International Journal of Inorganic Chemistry·Daniela MontesarchioLuigi Paduano
Dec 7, 2013·Cellular Signalling·Laurence A BoothPaul Dent
Jul 24, 2014·BioMed Research International·M S MohamedSamar S Fathallah
May 9, 2015·Cell Death and Differentiation·A R D Delbridge, A Strasser
Jun 18, 2015·Molecular Medicine Reports·Frederic BuxantSven Saussez
Jul 15, 2015·Dalton Transactions : an International Journal of Inorganic Chemistry·Domenica MusumeciDaniela Montesarchio
Oct 2, 2015·Mini Reviews in Medicinal Chemistry·Mohammad AbidAmir Azam
Oct 16, 2015·Journal of Cancer Research and Therapeutics·Rani OjhaShrawan Kumar Singh
Nov 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eileen WhiteChang S Chan

❮ Previous
Next ❯

Citations

May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Priscila Pereira Silva-CaldeiraElene Cristina Pereira-Maia
Apr 16, 2021·Chemistry : a European Journal·Nazia Nayeem, Maria Contel
Jul 3, 2021·Cells·Ferdinando Chiaradonna, Domenica Scumaci

❮ Previous
Next ❯

Methods Mentioned

BETA
confocal microscopy

Software Mentioned

ToThyCholRu

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.